For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 321,532 | |||
| General and administrative | 50,110 | |||
| Total operating expenses | 371,642 | |||
| Loss from operations | -371,642 | |||
| Interest income | 5,868 | |||
| Other income | 4,151 | |||
| Change in fair value of warrant liabilities | 334,358 | |||
| Total other income (expense), net | -324,339 | |||
| Net loss | -695,981 | |||
| Unrealized gain on available for sale marketable securities | 19 | |||
| Total other comprehensive income | 19 | |||
| Comprehensive loss | -695,962 | |||
| Basic EPS | -70.5 | |||
| Diluted EPS | -70.5 | |||
| Basic Average Shares | 9,871,866 | |||
| Diluted Average Shares | 9,871,866 | |||
Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. (VOR)